13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D Filed 2026-10-23 Event 2026-10-15 SEC 0001477932-26-006433 →

James Russell Revocable Trust → ABEONA THERAPEUTICS INC. ABEO

Stake: 6.10% Shares: 3,479,963 CUSIP: 00289Y206 Class: Common Stock, $0.01 par value
Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 32/100
  • Active Schedule 13D filer baseline
  • Net insider selling ($208,431 Code-S in ±30d)
  • 7 NPORT-P mutual funds holding CUSIP
  • Elevated short days-to-cover (11.6 DTC)

Item 4 — Purpose of Transaction

The Reporting Persons originally acquired the Shares for investment purposes and reported their beneficial ownership on Schedule 13G. Over time, based on their review of the Issuer's public filings, press releases and other public communications, the Reporting Persons became concerned regarding the Issuer's operational execution, the consistency of management's public statements with subsequent operating results, and the Issuer's governance. Beginning in May 2026, the Reporting Persons communicated their concerns (as a shareholder in an informal manner), to the Issuer's management and board of directors (the "Board"). On October 14, 2026, Mr. Russell met electronically with two members of the Board: Faith L. Charles, Interim Chair of the Board and Chair of the Board's Nominating and Corporate Governance Committee, and Keith A. Goldan, Chair of the Board's Audit Committee. At that meeting, Mr. Russell presented a summary of his concerns, including the Board should consider adding additional independent directors, and expressed his view that a change in the Issuer's executive leadership should be explored. Mr. Russell also requested a written response from the Board. On October 15, 2026, Ms. Charles advised Mr. Russell that each of the concerns discussed have been shared with the full Board and should any action be taken, communications when released by the Issuer should be reviewed versus directly to him. The Reporting Persons intend to continue to engage with the Board and management regarding the business and affairs of the Issuer, including, without limitation, Board composition and leadership. Depending on the Board's response and other factors, the Reporting Persons may take further actions, which may include proposing or seeking to nominate candidates for election as directors at the Issuer's 2027 annual meeting of stockholders, voting against one or more incumbent directors, communicating with other stockholders of the Issuer, or seeking representation on the Board, directly or through designees. The Reporting Persons will not vote any Shares acquired on or after October 15, 2026 at any meeting of stockholders of the Issuer. Except as set forth herein, the Reporting Persons have no present plans or proposals that relate to or would result in any of the matters set forth in subparagraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons intend to review their investment on a continuing basis and, depending on various factors, may in the future take such actions with respect to their investment as they deem appropriate, including acquiring additional Shares or disposing of Shares, in each case subject to applicable law, or changing their intention with respect to any of the matters referenced in this Item 4.

Cross-References

Insider Activity (last 365d)
9 transactions
0 buys · 9 sales · 0 awards/exercises
Issuer Cluster
2 13D/G filings on this issuer
1 other filing besides this one
Filer Track Record
1 filings by this filer
0 other filings in the data moat
Short Interest · settle 2026-09-30
DTC 11.57
16,882,889 shares short · +7.2% vs prior

Form 4 Insider Transactions · last 365d

DateInsiderRoleTypeSharesPriceValue
2026-09-29 Seshadri Vishwas director, officer Sale 19,608 $5.16 $101K
2026-09-29 Vazzano Joseph Walter officer Sale 9,191 $5.16 $47K
2026-09-29 O'Malley Brendan M. officer Sale 6,727 $5.16 $35K
2026-09-29 Vasanthavada Madhav officer Sale 4,902 $5.16 $25K
2026-07-09 Vazzano Joseph Walter officer Sale 24,880 $6.96 $173K
2026-07-09 Seshadri Vishwas director, officer Sale 67,971 $6.96 $473K
2026-07-09 O'Malley Brendan M. officer Sale 12,050 $6.96 $84K
2026-07-09 Vasanthavada Madhav officer Sale 12,606 $6.96 $88K
2026-06-15 Silverstein Christine Berni director Sale 18,160 $5.71 $104K

Other 13D/G Filings on ABEONA THERAPEUTICS INC.

FiledFormFilerStakeShares
2020-04-22 SC GREAT POINT PARTNERS LLC — — view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →